# US 2019/0153445 A1 · Composition For Delivery Of Genetic Material

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0153445 A1
- Document ID: US20190153445A1
- Status: Published application
- Kind: A1
- Application number: 16/264,257
- Filed: 2019-01-31
- Published: 2019-05-23
- Earliest claimed: 2009-04-17
- Assignees: Oxford University Innovation Limited
- Applicants: Oxford University Innovation Limited
- Inventors: Yiqi Seow; Lydia Alvarez; Matthew Wood
- Web page: https://patentgrep.com/patent/US20190153445A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 47/42: Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34)
- A61K 47/6901: {Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors}
- A61K 48/0025: {wherein the non-active part clearly interacts with the delivered nucleic acid}
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 7/06: having 5 to 11 amino acids
- C07K 14/005: from viruses
- C07K 14/435: from animals; from humans
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C07K 2319/035: containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/315: Phosphorothioates
- C12N 2320/32: Special delivery means, e.g. tissue-specific
- C12N 2760/20022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/20031: Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates to exosomes, loaded with genetic material and methods of producing them and to the use of such exosomes for delivering genetic material in vivo, in particular the use of such exosomes in methods of gene therapy or gene silencing.

## Claims

### Claim 1

A composition comprising exosomes comprising electroporated exogenous genetic material, wherein the electroporated exogenous genetic material is unnatural modified oligonucleotide.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the unnatural modified oligonucleotide may be anyone or more of the following: a transplicing oligonucleotide, a morpholino (PMO), an antisense oligonucleotide (ASO), a peptide nucleic acid (PNA), an miRNA, an shRNA or an siRNA.

### Claim 3 (depends on 1)

The composition according to claim 1, wherein, the modification of the oligonucleotide is selected from any one or more of the following list: thio-nucleotide, phosphodiester, 2′O-methyl, 2′ methoxy-ethyl, phosphoramidate, methylphosphonate, phosphorothioate backbone chemistry, morpholino (PMO) or peptide nucleic acid (PNA).

### Claim 4 (depends on 1)

The composition according to claim 1, wherein the oligonucleotide is single-stranded or double stranded.

### Claim 5 (depends on 1)

The composition according to claim 1, wherein the exosomes comprise a targeting moiety expressed on the surface of the exosome.

### Claim 6 (depends on 1)

The composition according to claim 1, wherein the exosomes comprise an exosomal transmembrane protein which has been modified to incorporate the targeting moiety.

### Claim 7 (depends on 6)

The composition according to claim 6 wherein the exosomal transmembrane protein is selected from: Lamp-1, Lamp-2, CD13, CD86, Flotillin, Syntaxin-3, CD2, CD36, CD40, CD4.0L, CD41a, CD44, CD45, ICAM-I, Integrin alpha* L1CAM, LFA-I, Mac-1 alpha and beta, Vti-1 A and B, CD3 epsilon and zeta, CD9, CDl 8, CD37, CD53, CD63, CD81, CD82, CXCR4, FcR, GiuR2/3, HLA-DM (MHC II), immunoglobulins, MHC-I or MHC-II components, TCR beta or tetraspanins.

### Claim 8 (depends on 1)

A method of delivering an unnatural oligonucleotide in vivo comprising delivering the composition of claim 1 to a selected tissue or cell type.

### Claim 9

A method of loading exosomes with an unnatural modified oligonucleotide by electroporation.

### Claim 10 (depends on 9)

The method of loading exosomes according to claim 9 wherein the unnatural modified oligonucleotide may be any one or more of the following: a transplicing oligonucleotide, a morpholino (PMO), an antisense oligonucleotide (ASO), a peptide nucleic acid (PNA), an miRNA, an shRNA or an siRNA.

### Claim 11 (depends on 9)

The method of loading exosomes according to claim 9, wherein the modification of the oligonucleotide is selected from any one or more of the following list: thio-nucleotides, phosphodiester, 2′O-methyl, 2′ methoxy-ethyl, phosphoramidate, methylphosphonate, phosphorothioate backbone chemistry, morpholino (PMO) or peptide nucleic acid (PNA).

### Claim 12 (depends on 9)

The method of loading exosomes according to claim 9, wherein the oligonucleotide is single-stranded or double stranded.

### Claim 13 (depends on 9)

The method of loading exosomes according to claim 9, wherein at least 20% of the oligonucleotide is loaded into the exosomes.
